The statistic functions module provides an execution environment for Linear Regression function and related indicators on Transcode Therapeutics. It emphasizes statistical functions describing dispersion and variability while keeping volatility, risk, and performance context in view.Please specify Time Period to run this model.
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Linear Regression model generates relationship between price series of Transcode Therapeutics and its peer or benchmark and helps predict Transcode Therapeutics future price from its past values.
Transcode Therapeutics Technical Analysis Modules
Most technical analysis of Transcode Therapeutics help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Transcode from various momentum indicators to cycle indicators. When you analyze Transcode charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. The company was incorporated in 2016 and is based in Boston, Massachusetts. Transcode Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 8 people. The stock overview for Transcode Therapeutics summarizes business drivers, financial profile, and market behavior. Current metrics include P/B of 6.21. Transcode Therapeutics has a market cap of 8.86 M, ROE of -17.63%.
Methodology
Unless otherwise specified, financial data for Transcode Therapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Transcode (USA Stocks:RNAZ) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The dataset for Transcode Therapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR. Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Transcode Therapeutics may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Tracking Transcode Therapeutics inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.
Generate Optimal Portfolios
Align your risk and return expectations
By capturing risk tolerance and investment horizon, Macroaxis optimization evaluates acceptable risk for target return profiles. The process summarizes how much risk can be taken for a given return goal.
A structured review of Transcode Therapeutics often starts with core financial statements and trend context. Key ratios help frame profitability, efficiency, and growth context for Transcode Therapeutics Stock. Outlined below are key reports that provide context for Transcode Therapeutics Stock:
Transcode Therapeutics has a market cap of 8.86 M, ROE of -17.63%. Use Your Equity Center to explore allocation context. This includes a position in Transcode Therapeutics within the portfolio mix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices.For information on how to trade Transcode Stock refer to our How to Trade Transcode Stock guide.Analysis related to Transcode Therapeutics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Portfolio Prophet module to use AI to generate optimal portfolios and find profitable investment opportunities.
The market value of Transcode Therapeutics is measured differently than book value, which reflects Transcode accounting equity. Transcode Therapeutics' market capitalization is 8.86 M. With a P/B ratio of 6.21, the market values Transcode Therapeutics well above its book equity. Enterprise value stands at 3.09 M. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
Note that Transcode Therapeutics' intrinsic value and market price are different measures derived from different inputs. For Transcode Therapeutics, key inputs include a P/B ratio of 6.21, and ROE of -17.63%. By contrast, market price reflects the level where buyers and sellers transact.
Ellen Johnson ยท Member of Macroaxis Editorial Board